Biopharma AI
ByHas China Now Overtaken the US at the Heart of Biotech Innovation?
Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…
Is Hong Kong Becoming Asia’s AI–Biopharma Hub?
Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’ partnership with Sanofi…
Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?
Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…
China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
Will Big Pharma’s Billion-Dollar AI Investments Reshape the US$2 Trillion Pharmaceutical Industry Faster Than the Next Blockbuster Drug?
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s Claude to 30,000 Employees Unlock Billions in AI-Driven Value and Redefine Biopharma’s Digital Future?
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
